生物
遗传增强
临床试验
基因转移
基因
生物信息学
遗传学
作者
Thomas Wirth,Nigel Parker,Seppo Ylä‐Herttuala
出处
期刊:Gene
[Elsevier]
日期:2013-04-23
卷期号:525 (2): 162-169
被引量:514
标识
DOI:10.1016/j.gene.2013.03.137
摘要
Two decades after the initial gene therapy trials and more than 1700 approved clinical trials worldwide we not only have gained much new information and knowledge regarding gene therapy in general, but also learned to understand the concern that has persisted in society. Despite the setbacks gene therapy has faced, success stories have increasingly emerged. Examples for these are the positive recommendation for a gene therapy product (Glybera) by the EMA for approval in the European Union and the positive trials for the treatment of ADA deficiency, SCID-X1 and adrenoleukodystrophy. Nevertheless, our knowledge continues to grow and during the course of time more safety data has become available that helps us to develop better gene therapy approaches. Also, with the increased understanding of molecular medicine, we have been able to develop more specific and efficient gene transfer vectors which are now producing clinical results. In this review, we will take a historical view and highlight some of the milestones that had an important impact on the development of gene therapy. We will also discuss briefly the safety and ethical aspects of gene therapy and address some concerns that have been connected with gene therapy as an important therapeutic modality.
科研通智能强力驱动
Strongly Powered by AbleSci AI